blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2931287

EP2931287 - DELPHINIDIN FOR COMBATING MELANOMA CELLS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  10.08.2018
Database last updated on 14.11.2024
FormerThe patent has been granted
Status updated on  01.09.2017
FormerGrant of patent is intended
Status updated on  03.05.2017
Most recent event   Tooltip17.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 19.08.2020  [2020/34]
Applicant(s)For all designated states
Sapiotec GmbH
Nikolausstrasse 20
97082 Würzburg / DE
[2017/21]
Former [2015/43]For all designated states
SapioTec GmbH
Nikolausstrasse 18
97082 Würzburg / DE
Inventor(s)01 / ROEWER, Norbert
Nikolausstrasse 20
97082 Würzburg / DE
02 / BROSCHEIT, Jens
Kerzenleite 35
97209 Würzburg / DE
 [2015/43]
Representative(s)Glawe, Delfs, Moll
Partnerschaft mbB von
Patent- und Rechtsanwälten
Postfach 13 03 91
20103 Hamburg / DE
[N/P]
Former [2017/40]Glawe, Delfs, Moll
Partnerschaft mbB
von Patent- und Rechtsanwälten
Postfach 13 03 91
20103 Hamburg / DE
Former [2015/43]Glawe, Delfs, Moll
Partnerschaft mbB von
Patent- und Rechtsanwälten
Rothenbaumchaussee 58
20148 Hamburg / DE
Application number, filing date13815384.628.11.2013
[2015/43]
WO2013EP74957
Priority number, dateDE20121022277711.12.2012         Original published format: DE102012222777
EP2013015090911.01.2013         Original published format: EP 13150909
[2015/43]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2014090583
Date:19.06.2014
Language:DE
[2014/25]
Type: A1 Application with search report 
No.:EP2931287
Date:21.10.2015
Language:DE
The application published by WIPO in one of the EPO official languages on 19.06.2014 takes the place of the publication of the European patent application.
[2015/43]
Type: B1 Patent specification 
No.:EP2931287
Date:04.10.2017
Language:DE
[2017/40]
Search report(s)International search report - published on:EP19.06.2014
ClassificationIPC:A61K38/17, A61K31/7042, A61K47/40, A61P35/00, A61K38/19, A61K31/352, // B82Y5/00
[2017/20]
CPC:
A61K31/352 (EP,US); A61K31/7042 (EP,US); A61K38/1793 (EP,US);
A61K38/191 (EP,US); A61K45/06 (EP,US); A61K47/6951 (EP,US);
A61P35/00 (EP); B82Y5/00 (EP,US) (-)
C-Set:
A61K31/7042, A61K2300/00 (EP,US)
Former IPC [2015/43]A61K31/7042, A61K45/00, A61K47/40, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2015/43]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:DELPHINIDIN ZUR BEKÄMPFUNG VON MELANOMZELLEN[2015/43]
English:DELPHINIDIN FOR COMBATING MELANOMA CELLS[2015/43]
French:DELPHINIDIN CONTRE LES CELLULES DE MÉLANOME[2017/20]
Former [2015/43]DELPHIDININE POUR LUTTER CONTRE DES CELLULES DE MÉLANOME
Entry into regional phase25.06.2015National basic fee paid 
25.06.2015Designation fee(s) paid 
25.06.2015Examination fee paid 
Examination procedure25.06.2015Examination requested  [2015/43]
04.09.2015Amendment by applicant (claims and/or description)
04.05.2017Communication of intention to grant the patent
28.08.2017Fee for grant paid
28.08.2017Fee for publishing/printing paid
28.08.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  04.05.2017
Opposition(s)05.07.2018No opposition filed within time limit [2018/37]
Fees paidRenewal fee
25.11.2015Renewal fee patent year 03
25.11.2016Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU28.11.2013
AL04.10.2017
CY04.10.2017
CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MK04.10.2017
MT04.10.2017
PL04.10.2017
PT04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
TR04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
[2020/34]
Former [2020/28]HU28.11.2013
CY04.10.2017
CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MK04.10.2017
MT04.10.2017
PL04.10.2017
PT04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
TR04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2020/16]HU28.11.2013
CY04.10.2017
CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MK04.10.2017
MT04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
TR04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2019/52]HU28.11.2013
CY04.10.2017
CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MK04.10.2017
MT04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2019/47]HU28.11.2013
CY04.10.2017
CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MT04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2019/31]HU28.11.2013
CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MT04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/52]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MT04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SI04.10.2017
SK04.10.2017
SM04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/45]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MT04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
SM04.10.2017
IE28.11.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/43]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
MT04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
SM04.10.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/40]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
RO04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
SM04.10.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/39]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
IT04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
SM04.10.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/38]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
SM04.10.2017
LU28.11.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/37]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
SM04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/36]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
PL04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/35]CZ04.10.2017
DK04.10.2017
EE04.10.2017
ES04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
MC04.10.2017
RS04.10.2017
SE04.10.2017
SK04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/24]ES04.10.2017
FI04.10.2017
HR04.10.2017
LT04.10.2017
LV04.10.2017
RS04.10.2017
SE04.10.2017
BG04.01.2018
NO04.01.2018
GR05.01.2018
IS04.02.2018
Former [2018/22]ES04.10.2017
FI04.10.2017
LT04.10.2017
NO04.01.2018
Cited inInternational search[YA]US2005013880  (MAGNUSON BERNADENE ANN [US], et al) [Y] 1-6,8-13 * page 1, paragraph 2 * * page 2, paragraph 24 * * page 3, paragraph 31 * * page 10, paragraph 121 * [A] 7;
 [YA]WO2006076387  (TROL AND PREVENTION HEALTH AND [US], et al) [Y] 1-6,8-13 * page 7, lines 14-21 * * claims 1,5 * [A] 7;
 [YDA]US2009270348  (ANTLE VINCENT [US]) [YD] 1-6,8-13 * page 12, paragraph 139 * [A] 7;
 [YA]  - Biolink, "Biolink synthetic anthocyanin molecules becomes cancer figthers", (20090522), pages 1 - 4, URL: http://www.biolink.no/biolink/cancer-article95-6.html, (20130221), XP002692595 [Y] 1-6,8-13 * page 2, paragraph 1 * [A] 7
 [YA]  - AFAQ FARRUKH ET AL, "Delphinidin, an anthocyanidin in pigmented fruits and vegetables, protects human HaCaT keratinocytes and mouse skin against UVB-mediated oxidative stress and apoptosis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, (200701), vol. 127, no. 1, ISSN 0022-202X, pages 222 - 232, XP002692596 [Y] 1-6,8-13 * abstract * [A] 7

DOI:   http://dx.doi.org/10.1038/sj.jid.5700510
 [YA]  - WANG L S ET AL, "Anthocyanins and their role in cancer prevention", CANCER LETTERS, NEW YORK, NY, US, vol. 269, no. 2, doi:10.1016/J.CANLET.2008.05.020, ISSN 0304-3835, (20081008), pages 281 - 290, (20080620), XP025496527 [Y] 1-6,8-13 * page 282, column r * [A] 7

DOI:   http://dx.doi.org/10.1016/j.canlet.2008.05.020
 [YA]  - SERAFINO ANNALUCIA ET AL, "Differentiation of human melanoma cells induced by cyanidin-3-O-beta-glucopyranoside", FASEB JOURNAL, (200409), vol. 18, no. 12, ISSN 0892-6638, pages 1 - 25, XP002692597 [Y] 1-6,8-13 * the whole document * [A] 7

DOI:   http://dx.doi.org/10.1096/FJ.04-1925FJE
 [YA]  - UEDA H ET AL, "EVALUATION OF A SULFOBUTYL ETHER BETA-CYCLODEXTRIN AS A SOLUBILIZING/STABILIZING AGENT FOR SEVERAL DRUGS", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, (19980901), vol. 24, no. 9, doi:10.3109/03639049809088532, ISSN 0363-9045, pages 863 - 867, XP009040590 [Y] 1-6,8-13 * discussion; page 867, column r * [A] 7

DOI:   http://dx.doi.org/10.3109/03639049809088532
 [A]  - VOERSMANN H ET AL, "Three dimensional melanoma treatment using the death ligand TRAIL", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (201209), Database accession no. PREV201200611221, XP009176203 [A] 6,7 * abstract *
    [ ] - JOURNAL OF INVESTIGATIVE DERMATOLOGY, 42ND ANNUAL MEETING OF THE EUROPEAN-SOCIETY-FOR-DERMATOLOGICAL-RESEARCH (ESDR); VENICE, ITALY; SEPTEMBER 07 -10, 2012, (201209), vol. 132, no. Suppl. 2, ISSN 0022-202X(print), page S129
by applicantUS5134127
 WO2009134347
    - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO
    - UEDA ET AL., "Evaluation of a Sulfobutyl Ether ß-Cyclodextrin as a Solubizing/Stabilizing Agent for Several Drugs", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, (1998), vol. 24, no. 9, doi:doi:10.3109/03639049809088532, pages 863 - 867, XP009040590

DOI:   http://dx.doi.org/10.3109/03639049809088532
    - BRUGGEN J.; SORG C., "Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies", CANCER IMMUNOL IMMUNOTHER, (1983), vol. 15, pages 200 - 205
    - RICCARDI C.; NICOLETTI I., "Analysis of apoptosis by propidium iodide staining and flow cytometry", NAT. PROTOC, (2006), vol. 1, doi:doi:10.1038/nprot.2006.238, pages 1458 - 1461, XP055130538

DOI:   http://dx.doi.org/10.1038/nprot.2006.238
    - PLÖTZ ET AL., "Mutual Regulation of Bcl-2 Proteins Independent of the BH3 Domain as Shown by the BH3-Lacking Protein Bcl-xAK", PLOS ONE, (2012), vol. 7, no. 4, page E34549
    - HEWETT P.W.; MURRAY J.C., "Immunomagnetic purification of human microvessel endothelial cells using Dynabeads coated monoclonal antibodies to PECAM-1", EUR J CELL BIOL, (1993), vol. 62, pages 451 - 454, XP009112370
    - HEWETT P.W.; MURRAY J.C., "Human microvessel endothelial cells: Isolation, culture and characterization", IN VITRO CELL BIOL, (1993), pages 823 - 830
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.